Search results for "liver transplantation."

showing 10 items of 354 documents

Reply: Selection criteria for liver transplantation in patients with hepatocellular carcinoma: Beyond tumor size and number?

2007

OncologyTransplantationmedicine.medical_specialtyHepatologyTumor sizebusiness.industrymedicine.medical_treatmentLiver transplantationmedicine.diseaseGastroenterologyText miningInternal medicineHepatocellular carcinomamedicineSurgeryIn patientbusinessSelection (genetic algorithm)Liver Transplantation
researchProduct

Reply to: Selecting patients with hepatocellular carcinoma for transplantation

2007

OncologyTransplantationmedicine.medical_specialtyHepatologybusiness.industrymedicine.medical_treatmentLiver transplantationmedicine.diseaseTransplantationInternal medicineHepatocellular carcinomamedicineSurgerybusinessLiver Transplantation
researchProduct

Alpha-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular ca…

2013

Locoregional therapy (LRT) is being increasingly used for the management of hepatocellular cancer (HCC) in patients listed for liver transplantation (LT). Although several selection criteria have been developed, stratifications of survival according to the pathology of explanted livers and pre-LT LRT are lacking. Radiological progression according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) and alpha-fetoprotein (AFP) behavior was reviewed for 306 patients within the Milan criteria (MC-IN) and 116 patients outside the Milan criteria (MC-OUT) who underwent LRT and LT between January 1999 and March 2010. A prospectively collected database originating from 6 collabor…

OncologyTransplantationmedicine.medical_specialtyHepatologybusiness.industrymedicine.medical_treatmentMilan criteriaLiver transplantationmedicine.diseaseSurgeryTransplantationResponse Evaluation Criteria in Solid TumorsTumor progressionInternal medicineCarcinomaMedicineSurgeryRisk factorbusinessProspective cohort studyLiver Transplantation
researchProduct

NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options

2022

In light of a global rise in obesity and type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) represent an increasingly important underlying aetiology of hepatocellular carcinoma (HCC). HCCs arising from lipotoxicity-mediated chronic inflammation are characterised by several unique features: in contrast to virally driven HCC, up to 50% of NAFLD-HCC occurs in patients without cirrhosis and annual HCC incidence is comparatively low, complicating current surveillance strategies. On average, patients are older and are more frequently diagnosed at an advanced stage. While locoregional treatments are probably equally effective regardless of HCC aetio…

Oncologymedicine.medical_specialtyCarcinoma HepatocellularCirrhosisDiseaseType 2 diabetesNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicinemedicineHumansneoplasmsHepatologybusiness.industryLiver NeoplasmsFatty livermedicine.diseasedigestive system diseasesLiver TransplantationClinical trialTreatment OutcomeLiverHepatocellular carcinomaDisease ProgressionMetabolic syndromeSteatohepatitisbusinessJournal of Hepatology
researchProduct

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

2018

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein. (C) 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Oncologymedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentMilan criteriaLiver transplantation03 medical and health sciences0302 clinical medicineResectable Hepatocellular CarcinomaHepatocellular carcinomaliver transplantation radiofrequenza ablation contrast enhanced Ultrasound antiangiogenetic drugs immunotherapyInternal medicinemedicineHumansEarly Hepatocellular CarcinomaSocieties MedicalHepatologybusiness.industryLiver NeoplasmsGastroenterologyDisease ManagementCancermedicine.diseaseBCLC Stage3. Good healthEurope030220 oncology & carcinogenesisHepatocellular carcinomaPractice Guidelines as Topic030211 gastroenterology & hepatologyLiver cancerbusinessJournal of Hepatology
researchProduct

The road map toward an hepatitis C virus-free transplant population

2018

Antiviral therapy to eradicate hepatitis C virus (HCV) infection improves outcomes in patients undergoing liver transplantation (LT) for advanced chronic HCV with or without hepatocellular carcinoma. Traditionally, antiviral therapy focused on the use of interferon (IFN)-based regimens, with antiviral treatment initiated in the posttransplant period once recurrent HCV disease with fibrosis in the allograft was identified. The use of IFN-based therapy was limited in pretransplant patients with advanced liver disease. Earlier intervention, either before transplantation or early after LT, is now feasible with the advent of second-generation direct-acting antiviral agents (DAAs) with superior t…

Oncologymedicine.medical_specialtymedicine.medical_treatmentHepatitis C virusinfectious diseasePopulationHepacivirus030230 surgeryLiver transplantationmedicine.disease_causeclinical research/practiceinfection and infectious agents—viral: hepatitis CAntiviral Agents03 medical and health sciencesLiver diseasePostoperative Complications0302 clinical medicineeditorial/personal viewpointInternal medicinemedicineHumansImmunology and Allergyliver disease: infectiousPharmacology (medical)educationclinical research/practice; editorial/personal viewpoint; infection and infectious agents—viral: hepatitis C; infectious disease; liver disease: infectious; liver transplantation/hepatology; Immunology and Allergy; Transplantation; Pharmacology (medical)education.field_of_studyTransplantationbusiness.industrymedicine.diseaseHepatitis CLiver TransplantationTransplantationClinical trialhepatitis C infectious disease liver disease: infectious liver transplantation/hepatology [clinical research/practice editorial/personal viewpoint infection and infectious agents-viral]TolerabilityHepatocellular carcinoma030211 gastroenterology & hepatologybusinessliver transplantation/hepatology
researchProduct

Clinical course and management of acute and chronic viral hepatitis during pregnancy.

2014

Summary Pregnancy is a para-physiologic condition, which usually evolves without any complications in the majority of women, even if in some circumstances moderate or severe clinical problems can also occur. Among complications occurring during the second and the third trimester very important are those considered as concurrent to pregnancy such as hyperemesis gravidarum, intrahepatic cholestasis of pregnancy, HELLP syndrome and acute fatty liver of pregnancy. The liver diseases concurrent to pregnancy typically occur at specific times during the gestation and they may lead to significant maternal and foetal morbidity and mortality. Commonly, delivery of the foetus, even preterm, usually te…

Pediatricsmedicine.medical_specialtySettore MED/09 - Medicina InternaHepatitis Viral HumanHELLP syndromeAutoimmune hepatitisAcute fatty liver of pregnancyLiver diseaseHyperemesis gravidarumVirologyMedicineHumansPregnancy Complications InfectiousPregnancyanti-viral therapyHepatologybusiness.industryDisease Managementanti-viral therapy; liver disease; liver transplant; pregnancymedicine.diseaseLiver Transplantationliver transplantInfectious DiseasesImmunologyAcute DiseaseChronic DiseaseFemalepregnancybusinessViral hepatitisliver diseaseCholestasis of pregnancy
researchProduct

Influence of N-acetylcysteine on hepatic amino acid metabolism in patients undergoing orthotopic liver transplantation

2001

Experimental treatment with the antioxidant and glutathione precursor N-acetylcysteine (NAC) has been performed in orthotopic liver transplantation (OLT) to reduce reperfusion injury. To investigate the effect of NAC on the hepatic and intestinal amino acid metabolism, intraoperative amino acid exchange rates were studied in liver transplant recipients with high dose NAC treatment (n = 10) and in control patients (n = 9). Treatment with NAC was found to cause a loss of amino acids and increased urea nitrogen release from the liver graft. The net balance of most amino acids was shifted to increased hepatic release or decreased hepatic uptake. The initial cumulative splanchnic release of all …

PharmacologyAcetylcysteinechemistry.chemical_compoundAmino Acids AromaticmedicineHumansUreaSplanchnic CirculationAmino Acidschemistry.chemical_classificationTransplantationbusiness.industryBiological TransportMetabolismGlutathioneFree Radical ScavengersMiddle Agedmedicine.diseaseGlutathioneAmino acidAcetylcysteineLiver TransplantationTransplantationGlutamineProtein catabolismchemistryBiochemistryLiverReperfusion InjurybusinessReperfusion injuryAmino Acids Branched-Chainmedicine.drugTransplant International
researchProduct

2015

BACKGROUND Expensive pharmaceuticals are a major reason for cost intensive health care systems. Long-term immunosuppressive therapy plays a relevant role after organ transplantation. Patents of original drugs have expired and cheaper products are available. Little data are available regarding efficacy and safety of generic immunosuppressive agents. METHODS In this prospective study, 25 patients, who were clinically stable for a minimum of 2 years after liver transplantation, were converted from the original formulations of tacrolimus (TAC) and mycophenolate mofetil to the generics Tacpan (TAP) and Mowel (MOW). Patients were followed-up for 6 months. Results were compared retrospectively to …

PharmacologyPathologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentPharmaceutical ScienceImmunosuppressionLiver transplantationMycophenolateTacrolimusMycophenolic acidOrgan transplantationInternal medicineDrug DiscoverymedicineTrough levelProspective cohort studybusinessmedicine.drugDrug Design, Development and Therapy
researchProduct

Pentoxifylline in liver ischemia and reperfusion.

2013

Pentoxifylline is a methylxanthine compound which was first filed in 1973 and registered in 1974 in the United States by Sanofi-Aventis Deustchland Gmbh for the treatment of intermittent claudication for chronic occlusive arterial disease. This methylxanthine was later discovered to be a phosphodiesterase inhibitor. Furthermore, its hemorheological properties and its function as an inhibitor of inflammatory cytokines, like TNF- α, allowed researchers to study its effects in organ ischemia and reperfusion and transplantation. Although this drug has demonstrated beneficial effects, the mechanisms by which Pentoxifylline exerts a protective effect are not fully understood. This paper focuses o…

Phosphodiesterase InhibitorsIschemiaApoptosisPharmacologyPentoxifyllineProinflammatory cytokineIschemiamedicineAnimalsHumansPhosphodiesterase inhibitorPentoxifyllinebusiness.industryTumor Necrosis Factor-alphaLiver Diseasesmedicine.diseaseIntermittent claudicationLiver TransplantationTransplantationLiverAnesthesiaReperfusion InjurySurgeryTumor necrosis factor alphamedicine.symptombusinessReperfusion injurymedicine.drugJournal of investigative surgery : the official journal of the Academy of Surgical Research
researchProduct